Metastatic primary breast neuroendocrine neoplasms: a case series
Internal Medicine Journal · 2023-10 · 53 (10) · 1813-1818
DOI: 10.1111/imj.15961 ↗Kurz gefasst
Fachartikel in der Zeitschrift Internal Medicine Journal, online erschienen am 31.10.2022. Verfasst von Kathleen Batty und 9 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology, Royal North Shore Hospital, Sydney, New South Wales, Australia. Hauptthemen laut MEDLINE: Neuroendocrine Tumors, Breast Neoplasms, Carcinoma, Neuroendocrine, Neoplasms, Second Primary. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 17 Literaturangaben.
Abstract (Originalsprache)
Background
Breast neuroendocrine neoplasms represent a rare subtype of breast cancer which have not been well studied or characterised, particularly in the metastatic setting.
Aim
To present clinicopathological characteristics, treatment and outcomes of a series of patients with metastatic neuroendocrine carcinoma of the breast and review the current literature.
Methods
We performed a retrospective review to identify and describe patients with metastatic neuroendocrine carcinoma of the breast at our centre between 2011 and 2021. Medical records, pathology and imaging results were examined to evaluate the clinical and histopathological features as well as the treatment pathways and prognosis of these patients.
Results
We present a series of seven female patients with metastatic neuroendocrine carcinoma of the breast, as defined by the World Health Organization classification, over a period of 10 years (2011–2021) from a single centre. Median age at diagnosis was 48 years (range 39–63). Six of seven tissue samples expressed synaptophysin and chromogranin and were also oestrogen and progesterone receptor positive; median Ki‐67 index was 50% (range 20–90%). All seven patients had demonstrated avidity on 18 F‐FDG PET imaging, and the six who underwent 68 Ga‐DOTATATE PET all had significant avidity. Treatment modalities and sequencing varied, but all patients received chemotherapy during their disease course. Six patients received three or more lines of treatment. Median overall survival was 31.8 months (range 3.7–108.6). Median progression‐free survival (PFS) with first‐line therapy for metastatic disease was 5.8 months (range 1.8–37.8).
Conclusions
This series shows the use of multiple modalities in treating this disease, with different sequencing in different patients. Despite multiple modalities used in the first‐line setting, first‐line PFS remains short. Larger series and further molecular characterisation are required to aid clinicians in managing this condition and to guide optimal treatment sequencing to improve outcomes in this rare patient group.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Oncology, Royal North Shore Hospital, Sydney, New South Wales, Australia.
- Nuclear Medicine, Royal North Shore Hospital, Sydney, New South Wales, Australia.
- Bill Walsh Translational Cancer Research Laboratory, Kolling Institute, University of Sydney, Sydney, New South Wales, Australia.
- Patricia Ritchie Centre for Breast Cancer Research, Mater Hospital, North Sydney and University of Sydney, The Mater Hospital, Sydney, New South Wales, Australia.
- University of Sydney, Sydney, Australia.
ORCID-Profile: Kathleen Batty
Zitieren
APA
Batty, K., Taylor, A. M., Bernard, E. J., Diakos, C. I., Clarke, S. J., Guminski, A., Baron-Hay, S., Boyle, F., Pavlakis, N., & Chan, D. L. (2023). Metastatic primary breast neuroendocrine neoplasms: a case series. Internal Medicine Journal, 53(10), 1813-1818. https://doi.org/10.1111/imj.15961
Vancouver
Batty K, Taylor AM, Bernard EJ, Diakos CI, Clarke SJ, Guminski A, et al. Metastatic primary breast neuroendocrine neoplasms: a case series. Internal Medicine Journal. 2023;53(10):1813-1818. doi:10.1111/imj.15961
BibTeX
@article{Batty2023,
author = {Batty, Kathleen and Taylor, Amelia M and Bernard, Elizabeth J and Diakos, Connie I and Clarke, Stephen J and Guminski, Alexander and Baron-Hay, Sally and Boyle, Frances and Pavlakis, Nick and Chan, David L},
title = {Metastatic primary breast neuroendocrine neoplasms: a case series},
journal = {Internal Medicine Journal},
year = {2023},
volume = {53},
number = {10},
pages = {1813--1818},
doi = {10.1111/imj.15961}
}
EUVIMED